- Status:
- Topic selection
- Technology type:
- Medicine
- Decision:
- Not selected
- Reason for decision:
- Not eligible for Health Technology Evaluation guidance
- Further information:
- The 2024 voluntary scheme for branded medicines, pricing, access and growth states that NICE will continue to evaluate all new active substances and significant indications, except where there is a clear rationale not to do so. Decision makers have concluded that the clear rationale to not evaluate this product is due to commissioning under the NHS England commissioning medicines for children in specialised services policy being appropriate with Risankizumab being a paediatric extension of TA596. Please see eligibility criteria within the prioritisation manual for further information.
- ID number:
- 12204
Email enquiries
If you have any queries please email [email protected]
Related links
For further information on how we select topics for development, please see our page about prioritising our guidance topics